药物获批后获取恰当的证据。
Getting the Right Evidence After Drug Approval.
作者信息
Vreman Rick A, Leufkens Hubert G M, Kesselheim Aaron S
机构信息
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
National Health Care Institute (ZIN), Diemen, Netherlands.
出版信息
Front Pharmacol. 2020 Sep 9;11:569535. doi: 10.3389/fphar.2020.569535. eCollection 2020.
Abstract
To generate comparative evidence in a timely fashion for drugs without restricting or delaying access, value-based pricing and reimbursement could be conditioned on a prospective, post-approval evidence generation plan.
摘要
为了及时生成针对药物的比较性证据，同时又不限制或延迟药物的获取，基于价值的定价和报销可取决于一项前瞻性的批准后证据生成计划。
相似文献
1
Getting the Right Evidence After Drug Approval.药物获批后获取恰当的证据。
Front Pharmacol. 2020 Sep 9;11:569535. doi: 10.3389/fphar.2020.569535. eCollection 2020.
2
Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.亚太地区医疗技术的循证决策：来自印度、马来西亚、菲律宾和巴基斯坦的经验。
Value Health. 2009 Nov-Dec;12 Suppl 3:S18-25. doi: 10.1111/j.1524-4733.2009.00622.x.
3
Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.中国的药品定价与报销：整体为何小于部分之和。
Health Policy. 2016 May;120(5):519-34. doi: 10.1016/j.healthpol.2016.03.014. Epub 2016 Apr 12.
4
New Drug Reimbursement and Pricing Policy in Taiwan.台湾的新药报销与定价政策。
Value Health Reg Issues. 2018 May;15:127-132. doi: 10.1016/j.vhri.2018.03.004. Epub 2018 Apr 26.
5
Analysing criteria for price and reimbursement of orphan drugs in Spain.西班牙罕见病药物的定价与报销分析标准
Farm Hosp. 2019 Jul 1;43(4):121-127. doi: 10.7399/fh.11147.
6
Drug pricing and reimbursement decision making systems in Mongolia.蒙古国的药品定价与报销决策系统
J Pharm Policy Pract. 2017 Feb 27;10:11. doi: 10.1186/s40545-017-0098-6. eCollection 2017.
7
Comparing patient access to pharmaceuticals in the UK and US.比较英国和美国患者获取药品的情况。
Appl Health Econ Health Policy. 2006;5(3):177-87. doi: 10.2165/00148365-200605030-00004.
8
Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs.日本的药品定价与报销：为更快、更全面地获取新药。
Ther Innov Regul Sci. 2016 May;50(3):361-367. doi: 10.1177/2168479015619202.
9
Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.欧洲孤儿药报销与欧洲药品管理局的授权类型及基于卫生技术评估的决策之关系
Front Pharmacol. 2018 Nov 12;9:1263. doi: 10.3389/fphar.2018.01263. eCollection 2018.
10
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.定价与报销政策如何提高药品的可及性？从欧洲国家汲取的经验教训。
Appl Health Econ Health Policy. 2017 Jun;15(3):307-321. doi: 10.1007/s40258-016-0300-z.
引用本文的文献
1
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability.高成本一次性潜在治愈性疗法的管理进入协议：确定其适用性的框架和计算工具
Pharmacoeconomics. 2025 Jan;43(1):53-66. doi: 10.1007/s40273-024-01433-4. Epub 2024 Oct 5.
2
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.1995 年至 2020 年间欧洲药品管理局批准的肿瘤药物的附加获益和收益：回顾性队列研究。
BMJ. 2024 Feb 28;384:e077391. doi: 10.1136/bmj-2023-077391.
3
Synergy between health technology assessments and clinical guidelines for multiple sclerosis.健康技术评估与多发性硬化症临床指南的协同作用。
Clin Transl Sci. 2023 May;16(5):835-849. doi: 10.1111/cts.13492. Epub 2023 Mar 1.
4
Real World Data in Health Technology Assessment of Complex Health Technologies.复杂健康技术卫生技术评估中的真实世界数据
Front Pharmacol. 2022 Feb 10;13:837302. doi: 10.3389/fphar.2022.837302. eCollection 2022.
5
An urgent call to raise the bar in oncology.呼吁提高肿瘤学水平。
Br J Cancer. 2021 Nov;125(11):1477-1485. doi: 10.1038/s41416-021-01495-7. Epub 2021 Aug 16.
6
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.管理准入协议在不同环境和组合下对创新疗法的应用：可行性分析。
Int J Environ Res Public Health. 2020 Nov 10;17(22):8309. doi: 10.3390/ijerph17228309.
本文引用的文献
1
Generating comparative evidence on new drugs and devices after approval.批准后对新药和新器械生成对比证据。
Lancet. 2020 Mar 21;395(10228):998-1010. doi: 10.1016/S0140-6736(19)33177-0.
2
Comparative Approaches to Drug Pricing.药物定价的比较方法。
Annu Rev Public Health. 2020 Apr 2;41:499-512. doi: 10.1146/annurev-publhealth-040119-094305. Epub 2019 Dec 24.
3
4
Added therapeutic benefit and drug licensing.增加治疗益处与药物许可。
Nat Rev Drug Discov. 2019 Sep;18(9):651-652. doi: 10.1038/d41573-019-00068-x.
5
How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.在新的治疗选择的浪潮中，如何为慢性淋巴细胞白血病选择最佳的治疗和检测方法。
Curr Oncol Rep. 2019 Jul 20;21(8):74. doi: 10.1007/s11912-019-0819-x.
6
Current Policy and Practice for Value-Based Pricing.基于价值定价的现行政策与实践
Value Health. 2019 Jun;22(6S):S4-S6. doi: 10.1016/j.jval.2019.04.1918.
7
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.基于缓解率这一代谢终点的美国食品和药物管理局批准的癌症药物概述。
JAMA Intern Med. 2019 Jul 1;179(7):915-921. doi: 10.1001/jamainternmed.2019.0583.
8
Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.分析美国食品和药物管理局批准的治疗药物的批准后临床试验，这些药物无临床上市后要求或承诺。
JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.
9
The evolution of adaptiveness: balancing speed and evidence.适应性的演变：平衡速度与证据
Nat Rev Drug Discov. 2018 Dec;17(12):845-846. doi: 10.1038/nrd.2018.90. Epub 2018 Jul 6.
10
Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study.在欧盟，有条件批准药品的特定义务的上市后变更：一项回顾性队列研究。
Clin Pharmacol Ther. 2019 Feb;105(2):426-435. doi: 10.1002/cpt.1169. Epub 2018 Aug 12.
Zotero 插件